DIA MASC 2025

Medical Affairs 2.0: GenAI as the Catalyst for Change in Writing, MedComms, and Field Strategy

Digital and AI were hot topics underpinning many of the conversations at the DIA’s Medical Affairs and Scientific Communications (DIA MASC) forum I attended in March 2025, along with a focus on how we can utilize these tools to achieve impactful, engaging, and scientifically accurate communications that resonate with healthcare providers (HCPs) and patients. Along…...
Read More

Top Stories

Biopharma 2025 Trends

Biopharma Trends 2025: 3 Things to Know Right Now

The global business climate is ever-evolving, and 2025 looks...
AI in Medical Affairs & Medical Communications

Science, AI, and Human Ingenuity Converge to

Today, we're witnessing an unprecedented convergence of...

The Paradigm Shift from Traditional Scientific

In the rapidly evolving biopharma landscape, the approach to...
HCP engagement

A 4-Step Plan to Drive HCP Engagement

HCPs are a time-constrained and hard-to-engage audience. Learn how pharma can digitally engage HCPs better...
diversity and inclusion

Promoting Diversity and Inclusion in Clinical Trials – New England Journal of Medicine’s New Policy

Read this update on how the New England Journal of Medicine is trying to promote...
equity diversity and inclusion

How to Incorporate and Drive Equity, Diversity, and Inclusion in Medical Communications and Publications

A roadmap on how to drive advocacy for EDI in medical communications and publications and...
Medical Affairs - 2025

Vision 2025: Decoding the Medical Affairs Landscape

Medical Affairs is a critical strategic pillars of pharma. Read how Medical Affairs will evolve...
Using digital enhancements to maximize engagement

Using Digital Enhancements to Maximize Engagement: How Are Pharma and Publishers Embracing Digital?

Best practices to implement digital enhancements and measure effectiveness...
Building public trust in pharma

3 Factors That Will Help Pharma Build Public Trust

Pharma must engage with patients at all levels to build public trust...

Learn more ABOUT our company.